Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin Sells 1,130 Shares

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 1,130 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $40.23, for a total transaction of $45,459.90. Following the sale, the executive vice president now directly owns 244,955 shares in the company, valued at approximately $9,854,539.65. This trade represents a 0.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Polovin also recently made the following trade(s):

• On Wednesday, December 11th, Andrew Polovin sold 51,504 shares of Tempus AI stock. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56.

Tempus AI Trading Down 12.0 %

Shares of NASDAQ:TEM opened at $34.29 on Thursday. The stock has a fifty day moving average of $52.24. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $79.49. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Analysts Set New Price Targets

A number of research analysts recently weighed in on TEM shares. Loop Capital lifted their price objective on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Guggenheim started coverage on Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 price objective on the stock. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Piper Sandler reaffirmed a “neutral” rating and set a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Finally, Wolfe Research initiated coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $56.00.

Hedge Funds Weigh In On Tempus AI

Institutional investors have recently modified their holdings of the company. EFG Asset Management North America Corp. bought a new stake in Tempus AI in the 2nd quarter worth approximately $1,333,000. ARK Investment Management LLC bought a new stake in shares of Tempus AI in the 2nd quarter worth approximately $18,294,000. Northwestern University purchased a new stake in shares of Tempus AI in the 2nd quarter valued at $491,000. Alphabet Inc. bought a new position in shares of Tempus AI during the 2nd quarter valued at $54,289,000. Finally, Pier Capital LLC purchased a new position in Tempus AI in the 2nd quarter worth $2,301,000. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.